Why Novo Nordisk Stock Was Melting on Monday

Novo Nordisk (NYSE: NVO) stock was slimming down on Monday, but not in the way any investor in the Wegovy and Ozempic developer would want. An analyst's downgrade was the catalyst for some shareholders to exit the stock, and as a result, its price was down by more than 2% in mid-session trading.Well before market open, Argus's John Eade changed his Novo Nordisk recommendation to hold from his previous buy. His price target on the stock is now $56 per share. Image source: Getty Images.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool